NPI: 1144535444 · FORT COLLINS, CO 80524 · Clinic/Center · NPI assigned 08/11/2010
Authorized official THOMPSON, DAVID controls 20+ related entities in our dataset. Read more
| Authorized Official | THOMPSON, DAVID (CFO) |
| Parent Organization | POUDRE VALLEY HEALTH CARE INC |
| NPI Enumeration Date | 08/11/2010 |
Other providers sharing the same authorized official: THOMPSON, DAVID
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 9,843 | $595K |
| 2019 | 11,665 | $689K |
| 2020 | 6,640 | $436K |
| 2021 | 8,655 | $452K |
| 2022 | 10,704 | $667K |
| 2023 | 10,222 | $707K |
| 2024 | 5,455 | $320K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 22,108 | 20,866 | $1.29M |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14,968 | 14,043 | $1.26M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3,741 | 3,552 | $518K |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 5,153 | 4,839 | $444K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 6,885 | 6,462 | $233K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 454 | 404 | $37K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 658 | 641 | $24K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1,370 | 1,320 | $19K |
| 81025 | 2,259 | 2,145 | $17K | |
| 81003 | 4,927 | 4,660 | $9K | |
| 99204 | Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 35 | 32 | $4K |
| 71046 | Radiologic examination, chest; 2 views | 288 | 249 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 161 | 137 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 18 | 18 | $820.96 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 30 | 29 | $547.47 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 39 | 37 | $539.49 |
| 90686 | 17 | 16 | $269.55 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 52 | 51 | $6.65 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 21 | 16 | $2.34 |